As of 2024-12-12, the Intrinsic Value of Hikma Pharmaceuticals PLC (HIK.L) is
1,175.20 GBP. This HIK.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 1,964.00 GBP, the upside of Hikma Pharmaceuticals PLC is
-40.20%.
The range of the Intrinsic Value is 844.81 - 1,781.94 GBP
1,175.20 GBP
Intrinsic Value
HIK.L Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
844.81 - 1,781.94 |
1,175.20 |
-40.2% |
| DCF (Growth 10y) |
1,237.28 - 2,361.95 |
1,637.06 |
-16.6% |
| DCF (EBITDA 5y) |
1,289.86 - 1,868.39 |
1,546.15 |
-21.3% |
| DCF (EBITDA 10y) |
1,587.34 - 2,342.19 |
1,917.54 |
-2.4% |
| Fair Value |
501.68 - 501.68 |
501.68 |
-74.46% |
| P/E |
1,942.49 - 2,597.05 |
2,263.36 |
15.2% |
| EV/EBITDA |
1,722.41 - 3,452.97 |
2,435.91 |
24.0% |
| EPV |
1,324.71 - 1,792.24 |
1,558.48 |
-20.6% |
| DDM - Stable |
688.97 - 1,555.45 |
1,122.21 |
-42.9% |
| DDM - Multi |
1,115.30 - 1,873.10 |
1,391.00 |
-29.2% |
HIK.L Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
4,378.17 |
| Beta |
0.82 |
| Outstanding shares (mil) |
2.23 |
| Enterprise Value (mil) |
5,275.19 |
| Market risk premium |
5.98% |
| Cost of Equity |
10.00% |
| Cost of Debt |
5.64% |
| WACC |
9.00% |